HIV/HCV coinfection in clinical practice

Area of Science:

• Hepatology
• Virology
• Immunology

Background:

• Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) coinfection is common due to shared transmission routes.
• Highly active antiretroviral therapy (HAART) has improved HIV prognosis, making HCV a leading cause of morbidity and mortality in coinfected individuals.
• HIV exacerbates HCV infection, accelerating liver disease progression, including cirrhosis, end-stage liver disease, and hepatocellular carcinoma.

Purpose of the Study:

• To review current data on HCV treatment in coinfected patients.
• To assess the safety and efficacy of pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy for HCV in this population.
• To highlight the increased risk of hepatotoxicity from HAART in coinfected patients.

Main Methods:

• Review of recent clinical data and therapeutic guidelines.
• Analysis of treatment outcomes for pegylated interferon and ribavirin therapy in HCV/HIV coinfected patients.
• Evaluation of hepatotoxicity risks associated with HAART in coinfected individuals.

Main Results:

• Pegylated interferon and ribavirin therapy for HCV in coinfected patients is generally well-tolerated and safe.
• This therapy appears slightly less effective in coinfected patients compared to those with HCV monoinfection.
• HCV/HIV coinfected patients face a heightened risk of hepatotoxicity from HAART, necessitating close monitoring.

Conclusions:

• HCV treatment is a priority in coinfected patients due to accelerated liver disease progression.
• Pegylated interferon and ribavirin offer a viable treatment option, though efficacy may be reduced.
• Vigilant monitoring for HAART-related hepatotoxicity is crucial in managing HCV/HIV coinfection.